Evaluation of a programme for the prenatal screening for Down's syndrome by ultrasonographic nuchal translucency measurement and serum determinations in the first trimester of pregnancy;Evaluatie van een programma voor prenatale screening op Downsyndroom door echoscopische nekplooimeting en serumbepalingen in het eerste trimester van de zwangerschap

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 50, 2005, Pages 2795-2799

  Go, A T J I ^a   Hupkes, H W Dikker ^a   Lomecky, M ^a   Twisk, J ^a   Blankenstein, M A ^a   Van Vugt, J M G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPINE;

ADULT; ANALYTIC METHOD; ARTICLE; CALCULATION; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DOWN SYNDROME; FALSE POSITIVE RESULT; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; MATERNAL AGE; MEDICAL RECORD; NECK; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY DIABETES MELLITUS; PRENATAL SCREENING; SCREENING TEST;

ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; HUMANS; MASS SCREENING; MATERNAL AGE; NETHERLANDS; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS;

EID: 29144496017     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Kabinetsstandpunt prenatale screening. Brief staatssecretaris over nieuwe ontwikkelingen op het gebied van prenataal screenen. Kamerstuk 2003-2004, 29323, nr I. Den Haag: Tweede Kamer; 2003.
2. Grijseels EWM, Laudy JAM, Galjaard RJH, Wildschut HIJ. Prenataal onderzoek naar downsyndroom: medisch-technische overwegingen en dilemma's voortkomend uit de huidige toepassingsmogelijkheden. Ned Tijdschr Geneeskd. 2004;148:2166-71.
3. Pandya PP, Snijders RJ, Johnson SP, de Lourdes Brizot M, Nicolaides KB. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynaecol. 1995;102:957-62.
4. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet. 1998;352:343-6.
5. Müller F, Benattar C, Audibert F, Roussel N, Dreux S, Cuckle H. First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. Prenat Diagn. 2003;23:833-6.
6. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen. 2003;10:56-104.
7. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med. 2003;349:1405-13.
8. Schielen PCJI, Elvers LH, Loeber JG. Down syndroom risicoschatting in het ie trimester door bepaling van PAPP-A en vrij beta-hCG in serum. RIVM Report 199101008. Bilthoven: Rjjksinstituutvoor Volksgezondheid en Milieu; 2003.
9. Wald J, Densem JW, Cheng R, Collishaw S. Maternal serum free α- and free β-human chorionic gonadotrophin in pregnancies with insulin-dependent diabetes mellitus: implications for screening for Down's syndrome. Prenat Diagn. 1994;14:835-7.
10. Prenatale screening: Downsyndroom, neuralebuisdefecten, routineechoscopie. Rapportnr 2001/11. Den Haag: Gezondheidsraad; 2001.
11. Wald N, Leek I, editors. Antenatal and neonatal screening. 2nd ed. Oxford: Oxford University Press; 2000.
12. Müller MA, Pajkrt E, Bilardo CM. Echoscopische screening op het syndroom van Down vroeg in de zwangerschap: de nekplooimeting. Ned Tijdschr Geneeskd. 2002;146:793-8.